Healthcare Industry News: Esophageal Cancer
News Release - April 9, 2007
SpectraScience Hires Director of Sales and Marketing
SAN DIEGO, April 9 (HSMN NewsFeed) -- SpectraScience, Inc. (OTC Bulletin Board: SCIE ) announced today that David Mazepink has joined the Company as its Director of Sales and Marketing. He comes to us with proven sales and business development achievements in the Endoscopy industry, including Endoscopy Centers of America and its affiliates. Dave's experience covers almost 30 years of successful medical device sales and marketing.According to Jim Hitchin, President of SpectraScience, "Dave's experience in all phases of device sales will hopefully allow us quick entry into the pre-cancer screening marketplace with our WavSTAT(TM) product line."
The WavSTAT(TM) is used by physicians to diagnose tissue to determine if it is normal, pre-cancerous, or cancerous within one second. The WavSTAT(TM) System is currently approved by the FDA for use in detecting cancer in the colon. A new application for detecting pre-cancers in the throat, sometimes called Barrett's esophagus, is being tested in a clinical trial. Cancer of the esophagus is more than 90% fatal and may develop as a result of chronic heartburn or GERD. Esophageal Cancer is growing five times faster than all other cancers."
This news release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from the results discussed in the forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, the Form 10-KSB and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.
For further information contact Jim Hitchin at (858) 847-0200 x 201. www.spectrascience.com
Source: SpectraScience
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
